PMID- 23806529
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20190717
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 44
IP  - 10
DP  - 2013 Oct
TI  - Oncofetal protein IMP3: a new diagnostic biomarker for laryngeal carcinoma.
PG  - 2126-31
LID - S0046-8177(13)00151-2 [pii]
LID - 10.1016/j.humpath.2013.04.002 [doi]
AB  - An accurate diagnosis of laryngeal squamous cell carcinoma (LSCC) is essential 
      for patient management. The diagnosis of LSCC, especially in superficial 
      biopsies, can present a diagnostic challenge for pathologists. The ability to 
      diagnose LSCC would be greatly improved by the detection of a tumor-associated 
      antigen. IMP3 is an oncofetal protein associated with aggressive and advanced 
      tumors and is specifically expressed in malignant tumors but not found in benign 
      tissues. The aim of this study was to determine the expression and diagnostic 
      value of IMP3 in LSCC to determine whether it can serve as a diagnostic 
      biomarker. A total of 238 cases (laryngectomy, n = 121; biopsy, n = 117) 
      consisting of 11 laryngeal carcinoma in situ/severe dysplasia and 227 invasive 
      LSCC were examined by immunohistochemistry for IMP3 expression. IMP3 showed 
      strong cytoplasmic staining in 217 (92%) of 238 LSCCs regardless of histologic 
      grade. In addition, 58 (89%) of 65 small biopsies (</=5 mm in greatest dimension) 
      containing a minute amount of carcinoma were positive for IMP3. In contrast to 
      malignant tumors, IMP3 expression was not found in any of the adjacent benign 
      squamous epithelium (0/118 cases; 0%), mild or moderate dysplasia (0/139 cases; 
      0%), or pseudoepitheliomatous hyperplasia (0/99 cases; 0%). In summary, we are 
      the first to describe that IMP3 is a highly sensitive and specific biomarker for 
      LSCC. The expression of IMP3 in LSCC can be used as a positive biomarker to 
      increase the level of confidence in establishing a definitive diagnosis of a 
      malignancy in laryngeal biopsy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Chen, Kai
AU  - Chen K
AD  - State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, 
      China; Department of Radiology, Cancer Center, Sun Yat-sen University, Guangzhou, 
      Guangdong 510060, China.
FAU - Cornejo, Kristine M
AU  - Cornejo KM
FAU - Ye, Weijun
AU  - Ye W
FAU - Wu, Qiuliang
AU  - Wu Q
FAU - Liang, Jianzhong
AU  - Liang J
FAU - Jiang, Zhong
AU  - Jiang Z
LA  - eng
PT  - Journal Article
DEP - 20130625
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IGF2BP3 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma in Situ/*diagnosis/metabolism
MH  - Carcinoma, Squamous Cell/*diagnosis/metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*diagnosis/metabolism
MH  - Laryngectomy
MH  - Neoplasm Invasiveness
MH  - RNA-Binding Proteins/*metabolism
OTO - NOTNLM
OT  - Diagnostic biomarker
OT  - IMP3
OT  - Laryngeal carcinoma
OT  - Squamous cell carcinoma
EDAT- 2013/06/29 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/06/29 06:00
PHST- 2013/01/04 00:00 [received]
PHST- 2013/04/01 00:00 [revised]
PHST- 2013/04/03 00:00 [accepted]
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - S0046-8177(13)00151-2 [pii]
AID - 10.1016/j.humpath.2013.04.002 [doi]
PST - ppublish
SO  - Hum Pathol. 2013 Oct;44(10):2126-31. doi: 10.1016/j.humpath.2013.04.002. Epub 
      2013 Jun 25.